CD274 and neoplasm: These approaches are also predicted to synergize with checkpoint therapy either directly, by potentiating the effects of anti-CTLA-4 on sustaining T cell priming, or indirectly, by promoting the expansion of pre-existing tumor-specific T cells that can be targeted for increased intratumoral functionality by anti-PD-1/PD-L1 inhibitors3.